Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells

Stem Cells

Volumn 26, Issue 8, 2008, Pages 2142-2152

  De Sio, Francesca Romana Santoni ^a   Gritti, Angela ^a   Cascio, Paolo ^b   Neri, Margherita ^a   Sampaolesi, Maurilio ^c   Galli, Cesare ^d,e   Luban, Jeremy ^f   Naldini, Luigi ^a,g  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Istituto Sperimentale Italiano Lazzaro Spallanzani   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Embryonic stem cells; Gene transfer; Lentiviral vectors; Proteasome; Proteasome inhibitor; Somatic stem cells

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOPHILIN A; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS VECTOR; PROTEASOME; TACROLIMUS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; COMPETITIVE INHIBITION; DNA MODIFICATION; DRUG EFFECT; EMBRYONIC STEM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; LENTIVIRINAE; MESENCHYME CELL; MOLECULAR INTERACTION; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRION;

ANIMALS; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIV; HUMANS; INTERFERONS; LENTIVIRUS; MICE; NF-KAPPA B; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; STEM CELLS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 55049091782     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0705     Document Type: Article

References (64)

1. Singec I, Jandial R, Crain A et al. The leading edge of stem cell therapeutics. Annu Rev Med 2007;58:313-328.
2. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
3. Larochelle A, Dunbar CE. Genetic manipulation of hematopoietic stem cells. Semin Hematol 2004;41:257-271.
4. Goff SP. Host factors exploited by retroviruses. Nat Rev Microbiol 2007;5:253-263.
5. Goff SP. Genetic control of retrovirus susceptibility in mammalian cells. Annu Rev Genet 2004;38:61-85.
6. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 2007;81:1054-1061.
7. Goff SP. Retrovirus restriction factors. Mol Cell 2004;16:849-859.
8. Nisole S, Stoye JP, Saib A. TRIM family proteins: Retroviral restriction and antiviral defence. Nat Rev Microbiol 2005;3:799-808.
9. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004;4:868-877.
10. Stremlau M, Owens CM, Perron MJ et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-853.
11. Perez-Caballero D, Hatziioannou T, Zhang F et al. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005;79:15567-15572.
12. Wu X, Anderson JL, Campbell EM et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A 2006;103:7465-7470.
13. Schwartz O, Marechal V, Friguet B et al. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 1998;72:3845-3850.
14. Wei BL, Denton PW, O'Neill E et al. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol 2005;79:5705-5712.
15. Groschel B, Bushman F. Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol 2005;79:5695-5704.
16. Santoni de Sio FR, Cascio P, Zingale A et al. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006;107:4257-4265.
17. Goujon C, Riviere L, Jarrosson-Wuilleme L et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007;4:2.
18. Dueck M, Guatelli J. Evidence against a direct antiviral activity of the proteasome during the early steps of HIV-1 replication. Virology 2007;361:1-8.
19. Ailles L, Schmidt M, Santoni de Sio FR et al. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multipotent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther 2002;6:615-626.
20. Grande A, Piovani B, Aiuti A et al. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Blood 1999;93:3276-3285.
21. Migliaccio G, Di Pietro R, di Giacomo V et al. In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis 2002;28:169-180.
22. De Palma M, Montini E, Santoni de Sio FR et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005;105:2307-2315.
23. Cowan CA, Klimanskaya I, McMahon J et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 2004;350:1353-1356.
24. Gritti A, Frolichsthal-Schoeller P, Galli R et al. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci 1999;19:3287-3297.
25. Gritti A, Bonfanti L, Doetsch F et al. Multipotent neural stem cells reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci 2002;22:437-445.
26. Cavazzin C, Ferrari D, Facchetti F et al. Unique expression and localization of aquaporin-4 and aquaporin-9 in murine and human neural stem cells and in their glial progeny. Glia 2006;53:167-181.
27. Sampaolesi M, Torrente Y, Innocenzi A et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003;301:487-492.
28. Tagliafico E, Brunelli S, Bergamaschi A et al. TGFbeta/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. J Cell Sci 2004;117:4377-4388.
29. Dellavalle A, Sampaolesi M, Tonlorenzi R et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 2007;9:255-267.
30. Follenzi A, Ailles LE, Bakovic S et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000;25:217-222.
31. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001;8:739-758.
32. Unutmaz D, KewalRamani VN, Marmon S et al. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 1999;189:1735-1746.
33. Kootstra NA, Zwart BM, Schuitemaker H. Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. J Virol 2000;74:1712-1717.
34. Trobridge G, Russell DW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 2004;78:2327-2335.
35. Matlin KS, Reggio H, Helenius A et al. Pathway of vesicular stomatitis virus entry leading to infection. J Mol Biol 1982;156:609-631.
36. McClure MO, Sommerfelt MA, Marsh M et al. The pH independence of mammalian retrovirus infection. J Gen Virol 1990;71:767-773.
37. Sandrin V, Boson B, Salmon P et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002;100:823-832.
38. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-5441.
39. Maggirwar SB, Harhaj E, Sun SC. Activation of NF-kappa B/Rel by Tax involves degradation of I kappa B alpha and is blocked by a proteasome inhibitor. Oncogene 1995;11:993-998.
40. DiDonato JA, Mercurio F, Karin M. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol 1995;15:1302-1311.
41. Brockman JA, Scherer DC, McKinsey TA et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995;15:2809-2818.
42. Li J, Peet GW, Balzarano D et al. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem 2001;276:18579-18590.
43. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol 2004;2:401-413.
44. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264-267.
45. Ustrell V, Pratt G, Rechsteiner M. Effects of interferon gamma and major histocompatibility complex-encoded subunits on peptidase activities of human multicatalytic proteases. Proc Natl Acad Sci U S A 1995;92:584-588.
46. Müller U, Steinhoff U, Reis LF et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-1921.
47. Luban J. Absconding with the chaperone: Essential cyclophilin-Gag interaction in HIV-1 virions. Cell 1996;87:1157-1159.
48. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996;222:279-282.
49. Braaten D, Aberham C, Franke EK et al. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol 1996;70:5170-5176.
50. Walsh CT, Zydowsky LD, McKeon FD. Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 1992;267:13115-13118.
51. Keckesova Z, Ylinen LM, Towers GJ. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006;80:4683-4690.
52. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004;78:12800-12808.
53. von Laer D, Hufert FT, Fenner TE et al. CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood 1990;76:1281-1286.
54. Shen H, Cheng T, Preffer FI et al. Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol 1999;73:728-737.
55. Lee B, Ratajczak J, Doms RW et al. Coreceptor/chemokine receptor expression on human hematopoietic cells: Biological implications for human immunodeficiency virus-type 1 infection. Blood 1999;93:1145-1156.
56. Lawrence DM, Durham LC, Schwartz L et al. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 2004;78:7319-7328.
57. Schwartz L, Major EO. Neural progenitors and HIV-1-associated central nervous system disease in adults and children. Curr Hiv Res 2006;4:319-327.
58. Smith AL, Ganesh L, Leung K et al. Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J Exp Med 2007;204:421-430.
59. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17:1807-1819.
60. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol 1996;70:3551-3560.
61. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007;117:473-481.
62. Blagosklonny MV, Wu GS, Omura S et al. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996;227:564-569.
63. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437-2444.
64. Szutorisz H, Georgiou A, Tora L et al. The proteasome restricts permissive transcription at tissue-specific gene loci in embryonic stem cells. Cell 2006;127:1375-1388.